"Receptors, Progesterone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
Descriptor ID |
D011980
|
MeSH Number(s) |
D12.776.826.750.765
|
Concept/Terms |
Receptors, Progesterone- Receptors, Progesterone
- Progesterone Receptor
- Receptor, Progesterone
- Progestin Receptors
- Receptors, Progestin
- Progesterone Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Progesterone".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Progesterone".
This graph shows the total number of publications written about "Receptors, Progesterone" by people in this website by year, and whether "Receptors, Progesterone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 7 | 2 | 9 |
1996 | 8 | 4 | 12 |
1997 | 9 | 5 | 14 |
1998 | 7 | 3 | 10 |
1999 | 7 | 6 | 13 |
2000 | 13 | 5 | 18 |
2001 | 4 | 5 | 9 |
2002 | 10 | 4 | 14 |
2003 | 9 | 8 | 17 |
2004 | 10 | 6 | 16 |
2005 | 20 | 7 | 27 |
2006 | 19 | 9 | 28 |
2007 | 7 | 4 | 11 |
2008 | 5 | 6 | 11 |
2009 | 9 | 5 | 14 |
2010 | 9 | 7 | 16 |
2011 | 8 | 3 | 11 |
2012 | 11 | 5 | 16 |
2013 | 7 | 9 | 16 |
2014 | 3 | 1 | 4 |
2015 | 8 | 5 | 13 |
2016 | 6 | 6 | 12 |
2017 | 6 | 2 | 8 |
2018 | 5 | 5 | 10 |
2019 | 2 | 4 | 6 |
2020 | 8 | 5 | 13 |
2021 | 4 | 4 | 8 |
2022 | 4 | 0 | 4 |
2023 | 0 | 2 | 2 |
2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Progesterone" by people in Profiles.
-
ASO Visual Abstract: Real-World Implications of the SOUND Trial. Ann Surg Oncol. 2025 Jan; 32(1):121-122.
-
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study. Clin Cancer Res. 2024 Dec 02; 30(23):5304-5313.
-
Real-world quality-of-life of patients with HR+/HER2-?advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Res Treat. 2025 Feb; 209(3):613-627.
-
Cell-cycle machinery is critical in regulating uterine steroid hormone for embryo implantation and development. J Clin Invest. 2024 Nov 15; 134(22).
-
Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2025 Feb; 32(2):922-930.
-
Real-World Implications of the SOUND Trial. Ann Surg Oncol. 2024 Dec; 31(13):8776-8785.
-
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024 Oct 01; 10(10):1379-1389.
-
Generation of Oviductal Glycoprotein 1 Cre Mouse Model for the Study of Secretory Epithelial Cells of the Oviduct. Endocrinology. 2024 May 27; 165(7).
-
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol. 2024 Jul 01; 42(19):2281-2294.
-
Breast cryoablation for the palliative treatment of indolent subtype of multicentric triple-negative breast cancer. BMJ Case Rep. 2024 Apr 16; 17(4).